HUNGARIAN EXPERIENCES WITH LEVODOPA/CARBIDOPA INTESTINAL GEL IN THE TREATMENT OF ADVANCED PARKINSON'S DISEASE

被引:0
|
作者
Nagy, Helga [1 ,2 ]
Takats, Annannaria [1 ]
Toth, Adrian [1 ]
Bereczki, Daniel [1 ]
Klivenyi, Peter [3 ]
Dezsi, Livia [3 ]
Dibo, Gyoergy [3 ]
Vecsei, Laszlo [3 ,4 ]
Kovacs, Norbert [5 ]
Aschermann, Zsuzsa [5 ]
Komoly, Samue, I [5 ]
Varannai, Lajos [6 ]
Zemlenyi, Gyoengyi [6 ]
Valikovics, Attila [6 ]
机构
[1] Semmelweis Egyet, Neurol Klin, H-1083 Budapest, Hungary
[2] Orszagos Orvosi Rehabil Int, Budapest, Hungary
[3] Szegedi Tudomonyegyetem, Neurol Klin, Szeged, Hungary
[4] MTA SZTE, Szeged, Hungary
[5] Pecsi Tudomanyegyetem, Neurol Klin, Pecs, Hungary
[6] Borsod Abauj Zemplen Megyei Korhoz, Neurol Osztoly, Miskolc, Hungary
来源
IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE | 2014年 / 67卷 / 11-12期
关键词
advanced Parkinson's disease; motor and non - motor fluctuations; disturbing dyskinesias; effectiveness of LCIG therapy; results in Hungary; DUODENAL LEVODOPA INFUSION; CONTINUOUS DOPAMINERGIC STIMULATION; CONTINUOUS DRUG-DELIVERY; INTRAJEJUNAL LEVODOPA; NONMOTOR SYMPTOMS; MOTOR; EFFICACY; MULTICENTER; SAFETY;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
In the advanced Parkison's disease (PD) the late complications of levodopa therapy have to be considered: motor and/or non-motor fluctuations with or without disturbing dyskinesias. The non-motor fluctuations often influence the quality of life (QoL) in a much more negative way compared with the motor symptoms. In the treatment of advanced PD there are several device-aided methods - deep brain stimulation, apomorphine pump, levodopa/carbidopa intestinal gel (LCIG) - to improve the symptoms, the QoL, sometimes even in an individual, tailored custom form. The LCIG therapy was introduced in Hungary in 2011. Here we summarize the data of our patients: we have tested almost 60 patients and in 43 cases we have started this treatment. We analyze the duration of illness, levodopa therapy, motor and non-motor fluctuation of patients and present our experiences with the test phase and the chronic LCIG therapy via PEG/PEJ implantation. We paid attention to the surgery and device - depending side effects. Our experiences are similar to the international data. In patients selection "the right treatment, to the right patient, in the right time" is of importance.
引用
收藏
页码:385 / 389
页数:5
相关论文
共 50 条
  • [1] Levodopa--carbidopa intestinal gel for treatment of advanced Parkinson''s disease
    Fernandez, H. H.
    Odin, P.
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (05) : 907 - 919
  • [2] Problems related to levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease
    Udd, Marianne
    Lyytinen, Jukka
    Eerola-Rautio, Johanna
    Kenttamies, Anu
    Lindstrom, Outi
    Kylanpaa, Leena
    Pekkonen, Eero
    BRAIN AND BEHAVIOR, 2017, 7 (07):
  • [3] Levodopa/Carbidopa Intestinal Gel: Safety and Tolerability in Advanced Parkinson's Disease
    Lazaro Cebas, Andrea
    Caro Teller, Jose M.
    Pablos Bravo, Siria
    Serrano Garrote, Olga
    Ferrari Piquero, Jose M.
    LATIN AMERICAN JOURNAL OF PHARMACY, 2015, 34 (10): : 2016 - 2020
  • [4] Profile of levodopa/carbidopa intestinal gel and its potential in the treatment of advanced Parkinson's disease
    Skodda, Sabine
    JOURNAL OF PARKINSONISM AND RESTLESS LEGS SYNDROME, 2014, 4 : 53 - 62
  • [5] Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson's disease
    Valldeoriola, Francesc
    Jose Catalan, Maria
    Escamilla-Sevilla, Francisco
    Freire, Eric
    Olivares, Jesus
    Cubo, Esther
    Santos Garcia, Diego
    Calopa, Matilde
    Martinez-Martin, Pablo
    Carlos Parra, Juan
    Arroyo, Gloria
    Matias Arbelo, Jose
    NPJ PARKINSONS DISEASE, 2021, 7 (01)
  • [6] Long-term levodopa/carbidopa intestinal gel in advanced Parkinson's disease
    Caceres-Redondo, Maria T.
    Carrillo, Fatima
    Lama, Maria J.
    Huertas-Fernandez, Ismael
    Vargas-Gonzalez, Laura
    Carballo, Manuel
    Mir, Pablo
    JOURNAL OF NEUROLOGY, 2014, 261 (03) : 561 - 569
  • [7] The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease
    Lowin, Julia
    Sail, Kavita
    Baj, Rakhi
    Jalundhwala, Yash J.
    Marshall, Thomas S.
    Konwea, Henrietta
    Chaudhuri, K. R.
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (11) : 1207 - 1215
  • [8] Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States
    Amjad, Fahd
    Bhatti, Danish
    Davis, Thomas L.
    Oguh, Odinachi
    Pahwa, Rajesh
    Kukreja, Pavnit
    Zamudio, Jorge
    Metman, Leonard Verhagen
    ADVANCES IN THERAPY, 2019, 36 (09) : 2233 - 2246
  • [9] Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience
    Zibetti, M.
    Merola, A.
    Artusi, C. A.
    Rizzi, L.
    Angrisano, S.
    Reggio, D.
    De Angelis, C.
    Rizzone, M.
    Lopiano, L.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 (02) : 312 - 318
  • [10] Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson's disease in patients in Scotland and Wales
    Kalabina, Svetlana
    Belsey, Jonathan
    Pivonka, Dominic
    Mohamed, Biju
    Thomas, Chris
    Paterson, Brian
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (03) : 215 - 225